There is considerable interest in identifying peripheral biomarkers of schizophrenia.
Introduction
Schizophrenia is a devastating illness affecting approximately 1% of the population, with onset of psychosis typically in adolescence or early adulthood, a heterogenous symptom profile and significant social and occupational impairments 1 . Most of what is known about the neuropathology of schizophrenia is derived from studies of postmortem tissues. In vivo studies of biomarkers that reflect central processes would be ideal to examine neuropathological changes over the course of the illness. However, the challenges in obtaining tissues that may be informative of neuropathology of the disorder in living patients remains a limitation. Thus, the search for peripheral biomarkers that reflect neuropathological changes in schizophrenia is being actively pursued, but results have remained elusive. The study of circulating extracellular vesicles assayed peripherally is one promising approach to identify putative peripheral biomarkers of schizophrenia.
Extracellular Vesicles (EVs) include several distinct types of cell-derived vesicles that are released into the extracellular environment and influence adjacent as well as remote physiological and pathological processes [2] [3] [4] [5] . Exosomes refer to specific EVs that are typically 30-200nm in diameter and arise from late endosomes or multivesicular bodies (MVB) 6 . They are secreted into the extracellular space via a distinct secretory pathway and are detectable in biological fluids 3, 4 .
Exosomes can be secreted from a wide range of cell types into the extracellular space and can be assayed from biological fluids including blood, cerebrospinal fluid (CSF) and urine 7 . In the central nervous system (CNS), exosomes may be secreted by neurons, astrocytes, microglia and oligodendrocytes and appear to be involved in Ranganathan et al several physiological processes such as neuron-neuron or glial-neuron communication, regulation of myelination, regulation of stress and immune responses and modulation of synaptic plasticity 4, 5 . Exosomes have been shown to have the ability to cross the blood brain barrier, bidirectionally, in health and in illness, with their contents intact 2 , that makes them particularly attractive biomarkers for neuropathology. Analysis of exosomal content provides information about the cellular source of the exosome (particularly valuable in peripherally isolated exosomes), the inflammatory state of the cellular milieu, and ongoing physiological or pathological processes. The nucleic acid content, in particular, the microRNA content may help elucidate downstream cellular targets and potentially, the functional impact of the exosomes. Post mortem studies have shed light on the role of exosomes in the pathogenesis and disease progression of several neurodegenerative disorders (reviewed in Levy 2017) 8 . In parallel, the ability to identify markers of neuropathology in exosomes obtained from blood or CSF offers great promise in the development of peripheral biomarkers of illness. The study of exosomes in neuropathology has largely been limited to disorders such as Alzheimer's disease, Parkinson's disease, Lewy body dementia and traumatic brain injury (TBI) [8] [9] [10] [11] [12] [13] [14] [15] . The promising results of these studies has provided the impetus to search for similar biomarkers in psychiatric disorders such as schizophrenia.
Thus far, there have been only a handful of published studies examining exosomes in schizophrenia. Banigan et al 16 analyzed exosomes extracted from frozen post mortem brain tissue of patients with schizophrenia and bipolar disorder and healthy controls and reported greater expression of disease specific exosomal miRNAs in patients, specifically miR-497 in schizophrenia and miR-29c in bipolar disorder. More To our knowledge, there are no published studies in schizophrenia, examining neuropathology relevant protein cargo in circulating exosomes.
This cross-sectional study aimed to examine plasma exosomal protein content from patients with schizophrenia and matched healthy controls. Target proteins were identified based on the following criteria 1) cargo proteins previously identified in peripheral blood exosomal assays of disorders with significant neuropathology including dementias and TBI 20, 21 ; 2) proteins with relative cell specificity to the CNS neurons Plasma from a subset of schizophrenia subjects (n=8), was sampled twice, 4 weeks apart to examine the stability and reliability of the target protein signals identified in the exosomal isolates.
EVs isolation and characterization:
Exosomes were isolated from plasma using a standard exosome isolation kit (4478360, Invitrogen; Thermo Fisher Scientific, Waltham, MA) followed by 0.2 micron filtration and size determination using NanoSight using standardized procedures previously described 23 . The exosome pellet of size from 40-200 nm was dissolved in PBS, the concentration of the exosomes was determined using the NanoSight and protein was measured using BCA kit. Exosomes were lysed with RIPA buffer; protein concentration was measured prior to immunoblots. Exosomal protein concentration was measured by BCA kit and an equal amount of protein (20 µg) was loaded per well.
Nanoparticle tracking analysis ([NTA] NanoSight):
Vesicles were analyzed by nanoparticle tracking using the NanoSight NS300 system (Malvern, Great Malvern, UK).
Samples were administered and recorded under controlled flow, using the NanoSight syringe pump and script control system. For each sample, 5 videos of 60 seconds duration were recorded, with a 10-second delay between recordings, generating 5
Ranganathan et al replicate histograms that were averaged. Therefore, the typical number of completed tracks per sample was approximately 1200. The area under the curve was calculated using Prism-4 software version 4.03 (Graph Pad, San Diego, CA), to give average particle counts from these replicates. Particles ranging in size from 40-200 nm were considered exosomes consistent with previously published methods 24 (see sample image shown in Figure 1 ). Calnexin, a chaperone protein predominantly expressed in the endoplasmic reticulum, was included to demonstrate purity of the isolate from intracellular contaminants, specifically from the secretory pathway 7, 26 .
Western blot analysis:
Statistical Analysis: The demographic variables (age, gender and ethnicity) and substance use measures (nicotine and cannabis use) were summarized and compared for differences between the schizophrenia and the control groups. The distributions of exosome concentrations and modal exosomal sizes between the two groups were examined with boxplots and compared with Wilcoxon rank sum test. The proportion of samples in the schizophrenia and the control groups that tested positive on the immunoblot assays for each of the three target proteins were calculated. The sample proportions between groups were compared with Fisher's exact test of independence owing to the small number of samples examined in the study. Bonferroni correction was applied to adjust the p values for the independent comparisons of the three protein markers. Confidence intervals (95%) for the sample proportions were estimated using 'exact' method (Clopper-Pearson interval) due to the extreme the proportions noted in the sample 27 . Data analysis was carried out in R version 3.6.1 28 and the figures were generated with the packages tidyverse 29 and ggpubr 30 . Table 1) Table 1 . The schizophrenia and the control groups were comparable in age, gender and ethnicity. A significantly higher proportion of participants with schizophrenia compared to controls had cannabis and tobacco use.
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Results
Sample characteristics (
None of the control participants had received a diagnosis of any major psychiatric disorder or were currently receiving treatment for a chronic medical condition. Three healthy controls had lifetime history of exposure to cannabis, but none were current users of tobacco or cannabis. Schizophrenia patients were ill for a median (IQR) duration of 2.65 (5) years and ~80% of these participants were within the first six years of their illness. They were moderately to severely ill at the time of recruitment with a mean PANSS total score of 79.1 31 . The PANSS total and subscale scores for schizophrenia participants is provided in Table 1 . All except two patients were on oral or depot antipsychotic medications at the time of sample collection. (Figure 1 and 2 (Figures 3 and 4 ). It may be noted from the Western Blot image for GFAP ( Figure 3, panel A) , that the positive staining noted with the control samples yielded a very low intensity signal. However, owing to the inherent challenges in quantifying protein concentrations from Western blot signal intensities 33 , we did not formally quantify the protein concentrations in our analyses.
Exosome characteristics and concentration
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Synaptophysin immunopositivity was noted in in all 24 samples from participants with schizophrenia (100%, 95%CI: 85.8% -100%) and in 10 out of 12 (83.3%, 95%CI: 51.6%-97.9%) samples from control participants (Figures 3 and 4) . The difference in the proportion of participant samples within each group that tested positive for this synaptic vesicular protein was small and not statistically significant.
a-II Spectrin immunopositivity was detected in all samples from schizophrenia (100%, 95%CI: 85.8% -100% and control participants (100%, 95%CI: 73.5% -100%) ( Figures 3 and 4 ).
Finally, in the subset of 8 out of 24 (33.33%) schizophrenia participants in whom a second plasma sample (~4 weeks after initial sampling) was examined, the results of exosomal analyses remained unchanged from the previous timepoint and all samples tested positive for GFAP, Synaptophysin and a-II Spectrin.
Discussion
Our results demonstrate for the first time, a differential pattern of exosomal protein expression in schizophrenia compared to matched healthy controls. The ability to extract exosomes from plasma and identify neuropathology relevant signatures represents a significant advance in the quest for peripheral biomarkers of schizophrenia.
Specifically, we demonstrate expression of GFAP, a well-recognized marker of astrocytic pathology 34 , in plasma exosomes of all schizophrenia participants assessed unlike its absence in the majority of healthy control participants. This finding is particularly significant given the absence of group differences in the other markers and These findings are consistent with the neuroinflammatory hypothesis and the role of astro-glial pathology in schizophrenia 34, 35 . GFAP is highly expressed in astrocytes in the CNS, in a cell type specific fashion with minimal expression noted outside the CNS 36 and elevated GFAP expression is associated with increased astrocytic activation and inflammation 34 . Post mortem studies in schizophrenia demonstrate that GFAP is upregulated in the pre-frontal cortex in schizophrenia although results from other brain regions remain mixed [37] [38] [39] [40] [41] . These mixed results may be related to region specific differences in GFAP expression, diversity of astrocytes with respect to GFAP positivity and heterogeneity in schizophrenia or subsets within the disorder 34 GFAP expression may be affected by age 42, 44 and antipsychotic medications 45 .
GFAP expression detectable in brain tissue, CSF and serum increases with age 44 Amongst patients, there was no difference in GFAP expression noted with duration of illness, illness severity, substance use or exposure to antipsychotics. All the patients in this study had been exposed to antipsychotic medications, although two were not currently treated with antipsychotics. There is mixed data on the impact of antipsychotic medications on GFAP expression 45 . Larger, and ideally, longitudinal studies are needed to determine whether circulating exosomal GFAP expression varies by stage or duration of illness, symptom domains, antipsychotic medications, or other clinical factors including concomitant substance use. Interestingly, both the healthy controls participants whose exosome samples tested weakly positive for GFAP reported a history of lifetime cannabis use although none reported current cannabis or other substance use.
Ranganathan et al
Synaptophysin expression was observed in exosomal samples from both schizophrenia and healthy control participants in our study. Synaptophysin is a synaptic vesicle membrane protein expressed in neurons and neuroendocrine cells where it plays a critical role in the formation and regulation of synaptic vesicles 46 . Several studies have demonstrated reduced synaptophysin mRNA and protein expression in post mortem tissue of schizophrenia patients consistent with reduced synaptic vesicle density and function in schizophrenia as previously reviewed 47, 48 . Exosomal synaptophysin has also been examined in several neurodegenerative disorders such as Alzheimer's disease 12 We did not specifically extract NDE from plasma samples in this study. Further, the lack of a second patient group prevents our ability to account for the effect of chronic illness or stress. Finally, we did not study antipsychotic naïve patients in order to examine the effect of antipsychotic medications on exosomal protein expression. These limitations notwithstanding, these data strongly support the potential of exosomal proteins as peripheral biomarkers of neuropathology in schizophrenia.
Future Directions:
These initial results provide the impetus to examine a wider array of exosomal derived proteomic signatures in schizophrenia. Whether the observed differences are also present in other psychiatric disorders remains to be examined. Finally, studies are also needed to determine whether peripheral exosomal biomarkers represent trait markers of the disorder or vary by stage of illness, antipsychotic treatment, or other clinical factors given the heterogeneity of the schizophrenia. Fisher exact, p = 0.105 Fisher exact, p = 1
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Figure legends
